Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial SurveyDefense World · 3 days ago
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeeking Alpha · Sep 17, 2026
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyGlobeNewsWire · Sep 14, 2026
Tenaya Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewsWire · Sep 3, 2026
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301MarketBeat · Aug 18, 2026
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptSeeking Alpha · Aug 14, 2026Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.07 | -$0.20 | Miss |
| May 6, 2026 | -$0.09 | -$0.09 | Beat |
| Mar 11, 2026 | -$0.13 | -$0.12 | Beat |
| Nov 10, 2025 | -$0.15 | -$0.12 | Beat |
| Aug 6, 2025 | -$0.20 | -$0.14 | Beat |
| May 7, 2025 | -$0.18 | -$0.24 | Miss |